The worldwide genetics industry is expected to reach $2.9 billion by 2028

Company logo

Company logo

Dublin, June 16, 2022 (GLOBE NEWSWIRE) – The “Global Genetics Genetics Market Analysis Report, Industry Share and Industry Trends by Application (Oncology and Non-Oncology), by Product, by End User, by Regional Outlook and Forecast, 2022-2028” Report added to Show.

The global genetic market size is expected to reach $2.9 billion by 2028, growing at a market growth rate of 14.6% over the forecast period.

Epigenetics is the field of genetics that examines cellular and physiological changes produced by environmental or environmental variables that turn genes on and off and alter the cellular ability to read genes without being affected by genotype changes. Although the primary DNA or RNA sequence remains unchanged, epigenetics produces changes in the phenotype of the organism rather than the genotype. Genetic modifications are important for evolution because they are dynamic and change in response to environmental stimuli.

Epigenetics is a cutting-edge field focused on detecting and tracking phenotypic changes in genes caused by chromosomal alterations without affecting DNA sequences. Although other uses are growing, this area is most commonly associated with cancer research. Increased institutional and governmental cooperation, as well as funding for the development of innovative methods for disease detection and treatment, is expected to increase the demand for epigenetics, thus driving the market forward. For example, the University of Southampton and the University of Southampton Hospitals NHS Foundation Trust (UK) were awarded $1.57 million (£1 million) in February 2016 for research on cancer, infectious diseases and genetics.

The increasing global prevalence of cancer, as well as the increasing use of epigenetics in non-cancerous diseases, are two important factors driving the global epigenetics market. The number of cancer patients is expected to rise from 14.1 million in 2012 to 19.3 million by 2025, according to WHO projections. The number of new cancer cases in the United States increased to 1,688,780 in 2017 from 1,685,210 in 2016, according to the American Cancer Society.

Moreover, factors such as the increasing prevalence of cancer have led to increased funding for healthcare research and development, and it is expected that the increasing applications of non-cancer epigenetics will help the market to prosper even more. According to Globocan 2020, 19,292,789 new cancer cases of various types were recorded worldwide in 2020, with 9,958,133 cancer-related deaths. This global and widespread threat of cancer continues to be a major driving force behind the development of new cancer therapies that assist in risk assessment, early diagnosis and successful treatment monitoring.

Analysis of the impact of COVID-19

Given the importance of epigenetics in COVID-19 research, Covid has had a significant impact on the growth of the epigenetics market. According to research published in Clinical Epigenetics in October 2020 titled “Epigenetic influence in coronavirus infection and treatment,” genetic changes may play a major role in the outcome of coronavirus disease. Despite the fact that a variety of treatment alternatives are being investigated, more research is urgently needed to find a viable vaccine or safer chemotherapy drugs, including epigenetic therapies, to combat this viral epidemic and develop prevention against COVID-19 before And after exposure.

Market Growth Factors:

Increased demand for DNA methylation

The epigenetics market is driven by DNA methylation, which is the covalent binding of a methyl group to the cytosine ring, which inhibits transcription. Methyl-sensitive polymerase chain reaction (PCR) is defined as a disulfite-sensitive modification followed by polymerase chain reaction (MSP). Variations in MSP include real-time polymerase chain reaction to detect methylation, methylation light, and quantitative analysis of methylated alleles. Quantitative methods for DNA methylation are currently available, including allele-specific bisulfite sequencing, the Southern-based approach, bisulfite thermal sequencing, and bisulfite PCR followed by MALDI-TOF MS. Technological improvements are facilitating genome-wide site-specific DNA methylation assessment, promoting market expansion.

Increased incidence of cancer

The number of people diagnosed with cancer has increased dramatically across the world. The number of cancer patients is expected to rise from 14.1 million in 2012 to 19.3 million by 2025, according to WHO projections. Cancer is the second most common cause of death in the United States, causing approximately one in four deaths. According to the American Cancer Society, the number of new cancer cases in the United States is expected to rise to 1,688,780 in 2017 from 1,685,210 in 2016, while the total number of cancer-related deaths is expected to rise to 600,920. than 595,690 at the same time. Period of time.

Marketing Restriction Factor:

The huge cost of devices and the great need for standardization and clinical validation

Epigenetics research tools are expensive due to their broad features and functionality. For example, the NovaSeq 5000 and 6000 sequencer were released by Illumina in January 2017 and cost $850,000 and $985,000, respectively. TCO is increased by maintenance and a host of other indirect expenses, such as samples and consumables. Thus, many healthcare organizations are not pushing to adopt these tools. Pharmaceutical companies and research institutes require many of these systems. As a result, large sums of money will be required to purchase a number of expensive genomic devices. End users with tight budgets, such as academic research laboratories, have difficulty providing such systems.

Main topics covered:

Chapter 1. Market Scope and Methodology

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview Market and Scenario Configuration
2.2 Main factors affecting the market
2.2.1 Market Drivers
2.2.2 Market Restrictions

Chapter 3. Competition Analysis – Global
3.1 Cardinal matrix
3.2 Recent strategic developments at the industry level
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product launches and product expansions
3.2.3 Acquisition and Merger
3.3 The most important profit strategies
3.3.1 Key Leading Strategies: Relative Distribution (2018-2022)
3.3.2 Key strategic move: (Partnerships, Collaboration & Agreements: 2018, April – 2021, December) Key players

Chapter 4. Global Epigenetics Market, by Application
4.1 Global Oncology Market by Region
4.2 Global Non-Oncology Market by Region

Chapter 5. Global Morphology Market by Product
5.1 Global collections market by region
5.2 Global Reagents Market by Region
5.3 Global Enzymes Market by Region
5.4 Global Instruments Market by Region

Chapter 6. Global morphogenesis market by end user
6.1 Global Pharma and Biotechnology Companies Market by Region
6.2 Global Academic and Research Institutes Market by Region
6.3 Global Contract Research Organizations Market by Region

Chapter 7. Global Epigenetics Market by Region

Chapter 8. Company Profiles
8.1 Abcam plc
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Sectoral and Regional Analysis
8.1.4 Research and development expenditures
8.1.5 Recent Strategies and Developments: Partnerships, Collaborations and Agreements: Acquisition and Merger:
8.2 Agilent Technologies, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Sectoral and Regional Analysis
8.2.4 Research and development expenditures
8.2.5 Recent Strategies and Developments: Partnerships, Collaborations and Agreements: Acquisition and Merger:
8.3 Hologic, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Sectoral and Regional Analysis
8.3.4 Research and development expenditures
8.3.5 Recent Strategies and Developments: Acquisition and Merger:
8.4 Illumina, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research and development expenditures
8.4.5 Strategies and recent developments: Partnerships, Collaborations and Agreements:
8.5 Merck Group (Merck Millipore)
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Sectoral and Regional Analysis
8.5.4 Research and development expenditures
8.6 Birkin Elmer
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Sectoral and Regional Analysis
8.6.4 R&D Expenditure
8.6.5 Recent Strategies and Developments: Partnerships, Collaborations and Agreements: Product launches and expansions: Acquisition and Merger:
8.7 Qiagen NV
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research and development expenditures
8.7.5 Recent Strategies and Developments: Partnerships, Collaborations and Agreements:
8.8 Thermo Fisher Scientific, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Sectoral and Regional Analysis
8.8.4 Research and development expenditures
8.8.5 Recent Strategies and Developments: Partnerships, Collaborations and Agreements:
8.9 Search Zymo
8.9.1 Company Overview
8.9.2 Recent Strategies and Developments: Partnerships, Collaborations and Agreements:
8.10. Active Motif, Inc.
8.10.1 Company Overview
8.10.2 Recent Strategies and Developments: Partnerships, Collaborations and Agreements: Acquisition and Merger:

For more information about this report visit

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900